1214265-56-1 Usage
Uses
WZ3146 is an irreversiblely inhibitor against EGFR T790M.
Biological Activity
wz3146 is a novel, irreversible inhibitor that specifically inhibits phosphorylation of egfr(l858r0) and egfr(e746_a750) with ic50 values of 2nm each.wz3146 has been reported to inhibit the phosphorylation of egfr in the non–small-cell lung cancer (nsclc) cell lines [1]. wz3146 shows to suppress the growth of egfr t790m containing cell lines. besides, analysis of recombinant egfr t790m kinase incubated with wz3146 by electrospray mass spectrometry revealed stoichiometric addition of one inhibitor molecule to the protein. analysis of a pepsin digest of the modified protein by tandem ms identified cys 797 as the site of modification thus verifying covalent bond formation between wz3146 and egfr [2].
references
[1] thanyanan reungwetwattana, saravut j. weroha, julian r. molina. oncogenic pathways, molecularly targeted therapies, and highlighted
Check Digit Verification of cas no
The CAS Registry Mumber 1214265-56-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,1,4,2,6 and 5 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1214265-56:
(9*1)+(8*2)+(7*1)+(6*4)+(5*2)+(4*6)+(3*5)+(2*5)+(1*6)=121
121 % 10 = 1
So 1214265-56-1 is a valid CAS Registry Number.
InChI:InChI=1S/C24H25ClN6O2/c1-3-22(32)27-18-5-4-6-20(15-18)33-23-21(25)16-26-24(29-23)28-17-7-9-19(10-8-17)31-13-11-30(2)12-14-31/h3-10,15-16H,1,11-14H2,2H3,(H,27,32)(H,26,28,29)
1214265-56-1Relevant articles and documents
Discovery of selective irreversible inhibitors for EGFR-T790M
Zhou, Wenjun,Ercan, Dalia,Jaenne, Pasi A.,Gray, Nathanael S.
, p. 638 - 643 (2011/03/18)
Targeting the epidermal growth factor receptor kinase (EGFR) with ATP-competitive kinase inhibitors results in dramatic but short-lived responses in patients with EGFR mutant non small cell lung cancer. A series of novel covalent EGFR kinase inhibitors with selectivity for the clinically relevant T790M 'gatekeeper' resistance mutation relative to wild-type EGFR were discovered by library screening. A representative compound 3i was obtained through a systematic SAR study guided by mutant EGFR-dependent cellular proliferation assays.